Over the last few days several patients that have been taking Vascepa since inception, those first 5000 patients, have been coming in to get a look at what science has said about Vascepa. It works well, unless all the studies were doctored. A pity that many have been selling here and not waiting for what should be quite a ride over the next several months. Putting in an sNDA for a product already shown effective, meeting all required endpoints for ANCHOR already, on time for a multi-billion dollar market is a nice backdrop for early results showing the tremendous efficacy and safety profile of this monster drug. Oh yeah, there are some chances to talk about early results this week I believe, a few chances. Chances are excellent the early results match all the expectations since science doesn't go away because investors don't like GIA. Good luck.
Quick note, AMRN just set a nice double bottom today and looks to be an almost perfect entry point. The sNDA, while expected, portends a gigantic potential in Vascepa. Normally markets and biotech investors are drawn to such things.. Any selling here should be met with buyers pretty much from now on.